Drug Profile
Research programme: vascular disrupting agents - Madrigal Pharmaceuticals
Alternative Names: STA-9584Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Synta Pharmaceuticals
- Developer Madrigal Pharmaceuticals
- Class Small molecules
- Mechanism of Action Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called Madrigal Pharmaceuticals
- 24 Nov 2010 Preclinical development is ongoing in USA